Free Trial

Theravance Biopharma (TBPH) Stock Forecast & Price Target

Theravance Biopharma logo
$9.47 -0.14 (-1.46%)
(As of 11/22/2024 ET)

Theravance Biopharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
2

Based on 5 Wall Street analysts who have issued ratings for Theravance Biopharma in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 3 have given a hold rating, and 2 have given a buy rating for TBPH.

Consensus Price Target

$13.75
45.20% Upside
According to the 5 analysts' twelve-month price targets for Theravance Biopharma, the average price target is $13.75. The highest price target for TBPH is $21.00, while the lowest price target for TBPH is $9.00. The average price target represents a forecasted upside of 45.20% from the current price of $9.47.
Get the Latest News and Ratings for TBPH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Theravance Biopharma and its competitors.

Sign Up

TBPH Analyst Ratings Over Time

TypeCurrent Forecast
11/25/23 to 11/24/24
1 Month Ago
10/26/23 to 10/25/24
3 Months Ago
8/27/23 to 8/26/24
1 Year Ago
11/25/22 to 11/25/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$13.75$13.75$13.75$20.00
Forecasted Upside45.20% Upside60.82% Upside68.92% Upside91.02% Upside
Consensus Rating
Hold
Hold
Hold
Buy

TBPH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TBPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Theravance Biopharma Stock vs. The Competition

TypeTheravance BiopharmaMedical CompaniesS&P 500
Consensus Rating Score
2.40
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside45.20% Upside27,073.48% Upside7.66% Upside
News Sentiment Rating
Neutral News

See Recent TBPH News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/16/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00+84.28%
8/6/2024Leerink Partnrs
5 of 5 stars
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/6/2024TD Cowen
4 of 5 stars
 Lower TargetHold ➝ Hold$10.00 ➝ $9.00+14.50%
8/6/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$15.00 ➝ $10.00+4.28%
4/12/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$21.00+135.16%
1/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Inline

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:15 AM ET.


TBPH Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Theravance Biopharma is $13.75, with a high forecast of $21.00 and a low forecast of $9.00.

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TBPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBPH, but not buy additional shares or sell existing shares.

According to analysts, Theravance Biopharma's stock has a predicted upside of 45.20% based on their 12-month stock forecasts.

Theravance Biopharma has been rated by research analysts at HC Wainwright in the past 90 days.

Analysts like Theravance Biopharma less than other "medical" companies. The consensus rating for Theravance Biopharma is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TBPH compares to other companies.


This page (NASDAQ:TBPH) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners